Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Romania (1)

Russia (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

Ukraine (1)

United Arab Emirates (1)

Explore our news

18.07.2022
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® 

08.07.2022
STADA Health Report 2022: Europe experiencing worsening health conditions

Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…

25.06.2022
People with Parkinson’s are missing out on regular specialist advice in much of Europe

Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …

09.06.2022
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market

20.05.2022
22.04.2022
STADA brings in Berndt to further develop specialties and biosimilars offerings

Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars

06.04.2022
Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)

A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

18.03.2022
Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China

Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong…

19.01.2022
STADA expands production network with EUR50m project in Romania

STADA is preparing to meet demand for its expanding portfolio by investing almost EUR50 million in a supply-chain hub in Turda, Romania

05.01.2022
STADA sets up for success with Erin Federman as global biosimilars commercial head

Experienced expert Erin Federman will oversee commercialization of STADA’s biosimilars portfolio and pipeline

21.07.2021
Calliditas Therapeutics and STADA

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

12.07.2021
Enzymatica and STADA extend agreement on ViruProtect to Vietnam

Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (distributed by Enzymatica as ColdZyme®) in Vietnam.

17.06.2021
STADA Health Report 2021

A year that changed Europe’s health landscape

STADA Health Report 2022

Is Europe on the brink of a health collapse? Europe, early summer 2021: Covid vaccination programmes across Europe were in full flow, bringing the prospect of returning to life more like we knew it before the pandemic. But had the virus changed the way we lived irreversibly? By asking detailed questions of 30,000 people across 15 countries, the STADA Health Report 2021 brought to light the immediate short-term effects of the pandemic on the lives of Europeans.

One year later, STADA checked in with Europeans to learn what longer-term effects the pandemic has left on Europe’s health landscape: How is their mental health holding up? What is worrying them? All the answers can be found in the STADA Health Report 2022